6-K 1 d175986d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of June 2021

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒                     Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐                                              No ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________

 


In June 2021, Sanofi issued the press releases attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

   Description

Exhibit 99.1

   Press release dated June 29, 2021: Sanofi launches dedicated vaccines mRNA Center of Excellence

Exhibit 99.2

   Press release dated June 28, 2021: Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial

Exhibit 99.3

   Press release dated June 28, 2021: Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

Exhibit 99.4

   Press release dated June 25, 2021: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Exhibit 99.5

   Press release dated June 25, 2021: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ³50% PD-L1 expression

 

2


Exhibit Index

 

Exhibit No.

   Description

Exhibit 99.1

   Press release dated June 29, 2021: Sanofi launches dedicated vaccines mRNA Center of Excellence

Exhibit 99.2

   Press release dated June 28, 2021: Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial

Exhibit 99.3

   Press release dated June 28, 2021: Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

Exhibit 99.4

   Press release dated June 25, 2021: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma

Exhibit 99.5

   Press release dated June  25, 2021: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ³50% PD-L1 expression

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: June 30, 2021       SANOFI  
    By  

      /s/ Alexandra Roger

 
      Name:   Alexandra Roger  
      Title:   Head of Securities Law and Capital Markets  

 

4